60 Degrees Pharmaceuticals announced that it has granted the University of Kentucky a right of reference to the Company’s new drug application, NDA, for ARAKODA. ARAKODA is the Company’s anti-malarial approved by the U.S. Food and Drug Administration in 2018, indicated for the prophylaxis of malaria in patients aged 18 years of age and older.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SXTP:
- 60 Degrees Pharma Provides University of Kentucky with Right of Reference to ARAKODA® NDA in Support of SJ733 Phase IIb Study
- 60 Degrees Pharmaceuticals Inc trading halted, news pending
- 60 Degrees Pharmaceuticals, Inc. Announces 1:12 Reverse Stock Split
- 60 Degrees Pharmaceuticals announces 1-for-12 reverse stock split
- 60 Degrees Pharmaceuticals Awarded Contract with U.S. Army for ARAKODA® Supply Chain Upgrade Support
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue